FDA gives expedited approval to new groundbreaking pancreatic cancer drug

The FDA granted expedited approval to daraxonrasib, a first-of-its-kind pill for pancreatic cancer that targets Kras mutations driving tumor growth. The drug nearly doubles survival time compared to chemotherapy and offers fewer severe side effects.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.